TA Associates has completed a growth investment in Aldevron, a biotech working to develop plasmid DNA, proteins and antibodies. Founded in 1998, the company makes biologics for research, clinical and diagnostic applications, including treatments for cancer, infectious disease and other disorders.
For private equity firms like TA Associates, the biotech and pharmaceuticals sector has been a source of stunningly consistent activity. In 2016, PE investors completed 113 deals in the space, according to the PitchBook Platform—the fourth time in the past five years that figure was somewhere between 110 and 114 (the outlier: 2014, when 126 biotech & pharma deals were done).
Which firms have been leading the way? Here are the top investors in the biotech and pharmaceuticals industry since the start of 2012, including add-ons: